



BC Centre for Disease Control
Provincial Health Services Authority

Immunization Programs and Vaccine Preventable Diseases Service
655 West 12th Avenue
Vancouver, BC V5Z 4R4

Tel 604.707.2548
Fax 604.707.2515
www.bccdc.ca

Date: December 9, 2022

Administrative Circular: 2022:52

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

**Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products & Appendix E – Management of Biologicals**

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 Vaccine Eligibility

Content has been added for the Pfizer Bivalent booster dose for those 5 to 11 years of age under Fall 2022 Booster Dose.

Please remove page numbers: 1-3 dated October 28, 2022
Please add new page numbers: 1-3 dated December 9, 2022

COVID-19 Vaccine Comirnaty® (Pfizer-BioNTech) Adult/Adolescent (Gray Vial Cap)

BOOSTER DOSES: Content has been updated to indicate a booster dose of Pfizer-BioNTech bivalent COVID-19 mRNA vaccine is recommended for individuals 5-11 years of age at least 6 months after the primary series has been completed.

Please remove page numbers: 1-6 dated November 4, 2022
Please add new page numbers: 1-6 dated December 9, 2022

COVID-19 Vaccine Comirnaty® (Pfizer-BioNTech) Adult/Adolescent (Purple Vial Cap)

This biological product page has been removed as all lots of this vaccine are now expired.

Please remove page numbers: 1-6 dated November 4, 2022

Page 1 of 4

COVID-19 Vaccine COMIRNATY® (Pfizer-BioNTech) 6 months to 4 years of age (Maroon Vial Cap)

SPECIAL CONSIDERATIONS: Footnote A, which referenced the US CDC recommendation for co-administration of COVID-19 vaccine and another vaccine, has been removed as this recommendation is consistent with [NACI](#)'s updated recommendations.

Please remove page numbers: 1-6 dated October 28, 2022
Please add new page numbers: 1-5 dated December 9, 2022

COVID-19 Vaccine COMIRNATY® (Pfizer-BioNTech) 5-11 years of age (Orange Vial Cap)

BOOSTER DOSES: Content has been updated to indicate a booster dose of Pfizer-BioNTech bivalent COVID-19 mRNA vaccine is recommended for individuals 5-11 years of age at least 6 months after the primary series has been completed. A footnote has been added to indicate that [NACI](#) is currently only recommending one booster dose after the primary series for children 5-11 years of age. However, at the provider's discretion, a bivalent booster dose (as per recommended interval) could be offered to children considered at high risk of severe COVID-19 who have previously received a booster dose with the monovalent Pfizer-BioNTech COVID-19 mRNA vaccine. For other children 5-11 years of age, the bivalent vaccine is not recommended if a monovalent booster has already been received, but may be provided upon parent/guardian request.

Please remove page numbers: 1-5 dated November 4, 2022
Please add new page numbers: 1-6 dated December 9, 2022

COVID-19 Vaccine COMIRNATY® Bivalent (Pfizer-BioNTech) 5-11 Years of Age (Orange Vial Cap)

- A new biological product page has been created for the 5-11 year old presentation of COVID-19 Vaccine COMIRNATY® Bivalent (Pfizer-BioNTech).
- A booster dose of Pfizer-BioNTech bivalent COVID-19 mRNA vaccine is recommended for individuals 5-11 years of age at least 6 months after the primary series has been completed. [NACI](#) is currently only recommending one booster dose after the primary series for children 5-11 years of age. However, at the provider's discretion, a bivalent booster dose (as per recommended interval) could be offered to children considered at high risk of severe COVID-19 who have previously received a booster dose with the monovalent Pfizer-BioNTech COVID-19 mRNA vaccine. For other children 5-11 years of age, the bivalent vaccine is not recommended if a monovalent booster has already been received, but may be provided upon parent/guardian request.

- This product has an orange vial cap and an orange label border. The vial label includes “Original and Omicron BA.4/BA.5” to differentiate the bivalent formulation from the monovalent.
- This product requires dilution.

Please add page numbers: 1-5 dated December 9, 2022

COVID-19 Vaccine SPIKEVAX™ (Moderna) 6 Years of Age and Older (Red Vial Cap)

BOOSTER DOSES: Content has been updated to indicate a booster dose of Pfizer-BioNTech bivalent COVID-19 mRNA vaccine is recommended for individuals 5-11 years of age at least 6 months after the primary series has been completed.

Please remove page numbers: 1-5 dated November 4, 2022
Please add new page numbers: 1-5 dated December 9, 2022

COVID-19 Vaccine SPIKEVAX™ (Moderna) 6 months – 5 Years of Age (Royal Blue Vial Cap)

SPECIAL CONSIDERATIONS: Footnote A, which referenced the US CDC recommendation for co-administration of COVID-19 vaccine and another vaccine, has been removed as this recommendation is consistent with [NACI](#)'s updated recommendations.

Please remove page numbers: 1-4 dated August 8, 2022
Please add new page numbers: 1-4 dated December 9, 2022

Please also remove the Title Page and Table of Contents for Part 4 – Biological Products dated November 2022, and replace with the enclosed updated Title Page and Table of Contents dated December 2022.

Appendix E – Management of Biologicals

Guidance for Receiving and Handling the Pfizer-BioNTech COVID-19 mRNA Vaccine (including dry ice procedures)

The storage, shipping and handling information has been revised as follows:

- Content for Comirnaty® (purple vial cap and label border) for those 12 years of age and older has been removed as all lots of this product have expired.

Page 3 of 4

- Content for the monovalent and bivalent formulations of Comirnaty® (gray vial cap and label border) for those 12 years of age and older has been consolidated under one heading as the information is identical.
- The bivalent formulation of Comirnaty (orange vial cap and label border) for those 5-11 years of age has been included with the content for the monovalent formulation as the information is identical.

Please remove page numbers: 1-14 dated October 11, 2022
Please add new page numbers: 1-13 dated December 9, 2022

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,



Monika Naus MD MHSc FRCPC FACPM
Medical Director
Immunization Programs and Vaccine Preventable Diseases Service
BC Centre for Disease Control

pc:

Provincial Health Officer
Dr. Bonnie Henry

BC Ministry of Health,
Population & Public Health Division:

Brian Sagar
Senior Director Communicable Disease,
Population and Public Health Division

Bernard Achampong
Executive Director,
Public Health, Planning and Prevention,
Population and Public Health Division